



Taejoon Pharmaceutical Co., Ltd.

CEO
Tae Young Lee

Location
8 Daesagwan-ro 31 gil,
Yongsan-gu, Seoul, Republic
of Korea

Specialty
1. Ophthalmic IMD
2. Contrast media IMD
3. GI IMD

Tel / Fax / E-mail
T. 82-2-798-6601
F. 82-2-798-6608

Established in 1978, Taejoon is one of the leading specialty pharmaceutical companies in ophthalmology, radiology, and GI. With a global presence in the US, Europe, Asia and Africa, Taejoon has been building up company's future growth based on the business strategy by focusing its corporate resources; specialization, global marketing, and R&D innovation. In particular, Taejoon has acquired US and European GMP certifications to secure global competitiveness and maintains state-of-the-art manufacturing facilities.

Main Products

Product (Ingredient/Formulation)	Use	Exporting Countries	Remarks
Cyporin N Eye drop 0.05% (Cyclosporin)	Dry eye		Launched
Xalost-S Ophthalmic Solution (Latanoprost)	Glaucoma		Launched
Xalostplus Ophthalmic Solution (Latanoprost, Timolol maleate)	Glaucoma	EU, Hong Kong	Launched
Xalost Ophthalmic Solution (Latanoprost)	Glaucoma	EU, China, Nigeria	Launched
Gadobirx Pre-filled Syringe Injection (Gadobutrol)	Contrast enhancement of cranial and spinal MRI		Launched
Iobrix INJ 350 (Iohexol)	Contrast enhancement	Thailand, Philippines	Launched
CleanViewAL Powder (Polyethylene glycol3350)	Bowel cleansing		Launched

R&D Pipeline

Category	Project	Indication	Development process					
			Discovery	Preclinical	Phase I	Phase II	Phase III	Launch
IMD	Undecided	Eye disease	█	█				
IMD	Undecided	Eye disease	█	█	█	█	█	
IMD	Undecided	Eye disease	█	█				
IMD	Undecided	Gastrointestinal disease	█					
IMD	Undecided	Gastrointestinal disease	█	█				